On Wednesday, Mankind Pharma said that it has agreed with Dr Reddy’s Laboratories (DRL) to acquire two of its brands – one asthma and one infant care brand. The deal size was not disclosed.

• The 5 index signals smart traders watch before placing a single order
• Kwality Pharma Hits 52-Week High After Record FY26 Revenue
• Jay Bharat Maruti Hits 20% Upper Circuit on 287% Profit Surge
• ZEEL Falls 6% After Q4 Swings to Net Loss on Ad Revenue Miss
• Overnight Stock Market Movements: Key Developments 

Combihale, a drug used for treating asthma and chronic obstructive pulmonary disease, has a category market size of Rs 900 crore, growing at 14 per cent (IQVIA). Daffy, a soap-free moisturizing bar for infants, operates in a market category valued at Rs 1000 crore and is growing at 18 per cent (IQVIA).

The company said that the acquisition of Combihale is expected to strengthen Mankind’s presence in the inhalation respiratory market segment.